Alex Liripa Kwendra
Research Subjects
Alex Liripa Kwendra has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Augustin Mouinga-Ondémé
Unité des Infections Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville P.O. Box 769, Gabon
2 shared publications - Herman Chelo Ngadjole
Département de la Santé Publique, Université de Goma, Goma 2204, Democratic Republic of the Congo
2 shared publications - Ivan Sosthene Mfouo-Tynga
Unité des Infections Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville P.O. Box 769, Gabon
2 shared publications - Jéordy Dimitri Engone-Ondo
Unité des Infections Rétrovirales et Pathologies Associées, Centre International de Recherches Médicales de Franceville (CIRMF), Franceville P.O. Box 769, Gabon
2 shared publications - Salomon Batina Agasa
Département de Médecine Interne, Universités de Kisangani, Kisangani 2012, Democratic Republic of the Congo
2 shared publications - Eldridge Fedricksen Oloumbou
Unité des Infections Rétrovirales et Pathologies Associées, Centre Interdisciplinaire de Recherches Médicales de Franceville, Franceville P.O. Box 769, Gabon
1 shared publication
Latest Publications
- Open Access
- 10 October 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (10) , 286
Low Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo
The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democratic Republic of the Congo (DRC). Over an 11-month period, a prospective cohort study was conducted across 20 healthcare facilities in Bunia, Ituri Province. Targeted genotyping of the HIV-1 pol gene was performed, antiretroviral resistance mutations were identified, and genotypic sensitivity scores (GSSs) were calculated using the Stanford HIV Drug Resistance Database. Virological failure occurred in 12.3% (74/603) of participants, and targeted genotyping of the HIV-1 pol gene was attempted on 53 samples. This subgroup comprised 41 females (55.4%) and 33 males (44.6%), with a median age of 36 years (IQR: 17.0) and a median ART duration of 24 months. Subsubtype A1 predominated (38%), followed by subtypes G (26%) and D (9%); recombinant forms, led by CRF02_AG, accounted for 16%. Mutations associated with resistance to reverse transcriptase inhibitors were detected in 26.4% (14/53) of successfully sequenced samples, compared with 33.9% (18/53) for integrase strand-transfer inhibitors. Overall, GSS analysis revealed that 98% (50/51) of evaluable participants scored 3, whereas only 2% (1/51) scored below 3. This study demonstrates that DTG-based ART remains highly effective in Bunia. To optimize treatment outcomes and support progress toward the UNAIDS 95-95-95 targets, targeted interventions to enhance treatment adherence are urgently warranted.
- 10 October 2026
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 11 (10) , 286
Open AccessLow Prevalence of HIV-1 Antiretroviral Resistance Among Patients Experiencing Virological Failure on Dolutegravir-Based Regimens: A Prospective Cohort Study in Bunia, Democratic Republic of the Congo
The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democratic Republic of the Congo (DRC). Over an 11-month period, a prospective cohort study was conducted across 20 healthcare facilities in Bunia, Ituri Province. Targeted genotyping of the HIV-1 pol gene was performed, antiretroviral resistance mutations were identified, and genotypic sensitivity scores (GSSs) were calculated using the Stanford HIV Drug Resistance Database. Virological failure occurred in 12.3% (74/603) of participants, and targeted genotyping of the HIV-1 pol gene was attempted on 53 samples. This subgroup comprised 41 females (55.4%) and 33 males (44.6%), with a median age of 36 years (IQR: 17.0) and a median ART duration of 24 months. Subsubtype A1 predominated (38%), followed by subtypes G (26%) and D (9%); recombinant forms, led by CRF02_AG, accounted for 16%. Mutations associated with resistance to reverse transcriptase inhibitors were detected in 26.4% (14/53) of successfully sequenced samples, compared with 33.9% (18/53) for integrase strand-transfer inhibitors. Overall, GSS analysis revealed that 98% (50/51) of evaluable participants scored 3, whereas only 2% (1/51) scored below 3. This study demonstrates that DTG-based ART remains highly effective in Bunia. To optimize treatment outcomes and support progress toward the UNAIDS 95-95-95 targets, targeted interventions to enhance treatment adherence are urgently warranted.
- Open Access
Factors Associated with Viral Load Suppression Among People Living with HIV on Antiretroviral Therapy in Bunia, Northeastern Democratic Republic of Congo
Background: The fight against HIV in the Democratic Republic of Congo (DRC) is hindered by systemic challenges; notably, limited access to HIV viral load (VL) testing. Achieving VL suppression is the primary global target for eliminating HIV as a public health threat by 2030. This study aimed to determine the rate of VL suppression and identify associated factors among people living with HIV (PLHIV) receiving antiretroviral therapy (ART) in Bunia. Methods: A descriptive and analytical cross-sectional study was conducted among PLHIV receiving care at treatment sites in Bunia over a period of 11 months. Participants were selected using a two-stage sampling approach, consisting of non-random quota sampling followed by simple random sampling. The primary endpoint was the proportion of PLHIV achieving VL suppression, while associated factors were identified using multiple logistic regression analysis. Results: Overall, 603 PLHIV were enrolled, including 180 males (29.9%) and 423 females (70.1%). The median age was 40 years (IQR: 32–48), median duration on ART was 38 months (IQR: 15–91), and VL suppression was achieved by 75% of the participants. While this indicates significant progress, it remains below the UNAIDS 95-95-95 targets. Adherence to antiretroviral therapy (aOR = 139.43; 95% CI: 66.63–291.76; p < 0.001) and being female (aOR = 2.15; 95% CI: 1.02–4.53; p = 0.044) emerged as independent predictors of virological success. Conclusions: Enhancing access to VL testing and optimizing ART adherence support strategies are critical to improving VL suppression rates in Bunia. Addressing these gaps is essential for the DRC to align with the global health objectives.
Open AccessFactors Associated with Viral Load Suppression Among People Living with HIV on Antiretroviral Therapy in Bunia, Northeastern Democratic Republic of Congo
Background: The fight against HIV in the Democratic Republic of Congo (DRC) is hindered by systemic challenges; notably, limited access to HIV viral load (VL) testing. Achieving VL suppression is the primary global target for eliminating HIV as a public health threat by 2030. This study aimed to determine the rate of VL suppression and identify associated factors among people living with HIV (PLHIV) receiving antiretroviral therapy (ART) in Bunia. Methods: A descriptive and analytical cross-sectional study was conducted among PLHIV receiving care at treatment sites in Bunia over a period of 11 months. Participants were selected using a two-stage sampling approach, consisting of non-random quota sampling followed by simple random sampling. The primary endpoint was the proportion of PLHIV achieving VL suppression, while associated factors were identified using multiple logistic regression analysis. Results: Overall, 603 PLHIV were enrolled, including 180 males (29.9%) and 423 females (70.1%). The median age was 40 years (IQR: 32–48), median duration on ART was 38 months (IQR: 15–91), and VL suppression was achieved by 75% of the participants. While this indicates significant progress, it remains below the UNAIDS 95-95-95 targets. Adherence to antiretroviral therapy (aOR = 139.43; 95% CI: 66.63–291.76; p < 0.001) and being female (aOR = 2.15; 95% CI: 1.02–4.53; p = 0.044) emerged as independent predictors of virological success. Conclusions: Enhancing access to VL testing and optimizing ART adherence support strategies are critical to improving VL suppression rates in Bunia. Addressing these gaps is essential for the DRC to align with the global health objectives.